预处理方案是造血干细胞移植(HCT)操作中的一个至关重要的组成部分。**预处理方案的目的有两个：**

●**提供足够的免疫抑制以防止移植物排斥反应**

●**消除需行移植的基础疾病**

本专题将讨论各种**清髓性预处理(myeloablative conditioning, MAC)、非清髓性(nonmyeloablative, NMA)和减低强度预处理(reduced intensity conditioning, RIC)方案。**

针对特定疾病的预处理方案选择将于该疾病一起讨论。

移植物来源选择、移植物抗宿主病以及HCT的其他毒性和并发症详见其他专题。

●(参见 [“造血干细胞的来源”](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●(参见 [“急性移植物抗宿主病的临床表现、诊断和分级”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●(参见 [“急性移植物抗宿主病的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-acute-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●(参见 [“慢性移植物抗宿主病的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-chronic-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

定义HCT预处理方案的强度、毒性和对移植物抗肿瘤(graft-versus-tumor, GVT)效应的依赖性各异([图 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F87814&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))。HCT预处理方案包括清髓性(myeloablative, MA)、减低强度和非清髓性方案。虽然尚未达成完全的一致，但对这3种类型方案普遍接受的定义如下[[1-4](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/1-4)]：

●**清髓性**–**清髓性预处理方案由预计可破坏骨髓造血细胞的单药或数种药物联合组成，可在给药1-3周内引起严重的全血细胞减少。其引起的全血细胞减少持续很长时间，通常不可逆转，除非输注造血干细胞恢复造血功能。例如全身照射(total body irradiation, TBI)单剂≥5Gy，或[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(busulfan, Bu)>8mg/kg**。(参见下文[‘清髓性预处理方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H5))

●**非清髓性**–**非清髓性方案是指本身会引起轻微血细胞减少(但会引起显著的淋巴细胞减少)且可能不需要干细胞支持的方案。例如[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)加[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(cyclophosphamide, Cy)，联合或不联合[抗胸腺细胞球蛋白](https://www.uptodate.cn/contents/zh-Hans/133562?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(antithymocyte globulin, ATG)；或TBI≤2Gy联合或不联合嘌呤类似物。然而，此情况下进行的移植通常会变为清髓性的，因为植活的供者T细胞最终会清除宿主造血细胞，从而建立供者造血功能**。(参见下文[‘非清髓性和减低强度预处理方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89394696))

●**减低强度**–减低强度预处理(reduced intensity conditioning, RIC)方案是既不符合清髓性方案定义也不符合非清髓性方案定义的中间类别方案。此类方案导致的血细胞减少可能持续时间较长并导致显著的并发症和死亡，需要造血干细胞支持。[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)≤8mg/kg，或[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)≤140mg/m2一般被视为RIC方案。

**重要的是，设计这一命名是为了反映急性的方案相关毒性，而不是反映移植对基础疾病状态的总体疗效。** 另外，这些定义仅作为指导，并且在实践中，通常难以知道在不进行移植时某一方案将会有何影响。为了更好地比较这些方案在特定疾病状态中的疗效和毒性，有必要进行多中心随机试验。

方案的选择对于所有接受HCT的患者，没有最佳的预处理方案，临床实践因机构而异。预处理方案的选择应考虑受者的合并症、基础疾病、疾病状态、供者和移植物来源。预处理方案的对比见下文。(参见下文[‘清髓性方案 vs RIC方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H3000363872))

在选择预处理方案时应考虑以下原则：

●**受者共存疾病**–**患者的基础共存疾病通常指定了可能提供的预处理方案的类型。具有显著共存疾病的患者和年龄较大患者不适合采用清髓性预处理方案，但可能适合采用RIC或非清髓性方案**。(参见 [“确定适合异基因造血干细胞移植的患者”](https://www.uptodate.cn/contents/zh-Hans/determining-eligibility-for-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●**基础疾病**–基础疾病可能影响预处理方案的选择。**对于血液系统恶性肿瘤或增殖性疾病(例如，地中海贫血)的患者，根除宿主的造血干细胞是一个重要目标，会首选清髓性方案。而对于再生障碍性贫血或某些免疫缺陷状态患者，不需要进行根除处理，其预处理方案主要集中于免疫抑制以便于植活，所以可能适合采用减低强度的方案。**

某些遗传性骨髓衰竭疾病(例如范可尼贫血)特别容易受到化疗和放疗的毒性影响，应接受较低强度的预处理方案。(参见 [“Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)”, section on ‘Conditioning regimen’](https://www.uptodate.cn/contents/hematopoietic-cell-transplantation-hct-for-inherited-bone-marrow-failure-syndromes-ibmfs?sectionName=Conditioning+regimen&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H2008468709&source=see_link#H2008468709))

●**疾病状态**–**对于在移植时未达到完全缓解的血液系统恶性肿瘤患者，优选清髓性预处理方案。在某些情况下可能优选TBI，因为TBI可能根除许多化疗药物不能充分渗入的“庇护所”(如，中枢神经系统和性腺)的肿瘤细胞**。

●**排斥反应的风险**–移植物排斥反应更可能发生于：主要组织相容性抗原中人类白细胞抗原(human leucocyte antigen, HLA)不一致增加(如，HLA不相合)时；已暴露于次要组织相容性抗原(如，既往多次输血)的受者中；输注干细胞剂量较少的移植物后；以及接受去除T细胞的移植物后。**移植物排斥反应不太可能见于：干细胞剂量增加时；使用外周血祖细胞(而不是骨髓细胞)；移植物中的T细胞剂量较多；以及预处理方案中使用ATG时。自体HCT时，一般认为不会有移植排斥反应的风险。** (参见 [“造血干细胞移植中脐血移植物的选择”，关于‘细胞数量’一节](https://www.uptodate.cn/contents/zh-Hans/selection-of-an-umbilical-cord-blood-graft-for-hematopoietic-cell-transplantation?sectionName=%E7%BB%86%E8%83%9E%E6%95%B0%E9%87%8F&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H61604500&source=see_link#H61604500))

通常情况下，对于将行异基因HCT的体能状态良好的年轻患者，优选清髓性预处理方案，因为采用此类方案的经验更丰富。清髓性方案也是自体HCT的基础。对于基础疾病已得到充分控制的不适合采用清髓性方案的患者，可考虑RIC或非清髓性方案。清髓性方案、RIC和非清髓性方案间的选择，主要是基于各机构的偏好、各中心的经验、可用的资源和上述原则。

需要开展前瞻性随机试验来比较清髓性方案与非清髓性方案对特定疾病的治疗。一般来说，清髓性方案用于自体HCT和用于未达到缓解者的异基因HCT。

清髓性预处理方案

清髓性方案实例 — 如上所述，清髓性方案由预计可破坏骨髓造血细胞的单药或数种药物联合组成，清髓性方案可在给药1-3周内引起严重的全血细胞减少[[4](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/4)]。引起的全血细胞减少持续很长时间，通常不可逆转，除非输注造血干细胞恢复造血功能。常用的清髓性预处理方案包括([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F90901&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))[[5](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/5)]：

●**Cy/TBI**–该方案为：[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)120mg/kg的总剂量，分2日给予，联用TBI(12-14Gy)分4日给予。

●**Bu4/Cy**–该方案为：静脉给予[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)10-12mg/kg的总剂量，分4日给予，联用[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)120mg/kg，分2日给予。

●**Flu/Bu4**–该方案为：[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(口服16mg/kg或静脉给予12.8mg/kg)联用[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(120-180mg/m2)，分4日给予。

●**BEAM**–该方案包括：[卡莫司汀](https://www.uptodate.cn/contents/zh-Hans/94065?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(300mg/m2)，1日给予；[依托泊苷](https://www.uptodate.cn/contents/zh-Hans/92839?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(400-800mg/m2)，分4日给予；[阿糖胞苷](https://www.uptodate.cn/contents/zh-Hans/92802?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(800-1600mg/m2)，分4日给予；以及[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(140mg/m2)，1日给予。BEAM方案是非霍奇金淋巴瘤(non-Hodgkin lymphoma, NHL)或霍奇金淋巴瘤患者最常用的清髓性预处理方案。

●[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)–美法仑(200mg/m2)通常用作多发性骨髓瘤的自体HCT前的预处理方案。年龄较大患者(即，>70岁)、肾功能障碍患者或有多种共存疾病的患者使用较低的剂量(140mg/m2)。(参见 [“多发性骨髓瘤的自体造血干细胞移植”，关于‘预处理化疗’一节](https://www.uptodate.cn/contents/zh-Hans/multiple-myeloma-use-of-autologous-hematopoietic-cell-transplantation?sectionName=%E9%A2%84%E5%A4%84%E7%90%86%E5%8C%96%E7%96%97&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H8&source=see_link#H8))

●**CBV**–该方案包括：单剂[卡莫司汀](https://www.uptodate.cn/contents/zh-Hans/94065?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(300-500mg/m><662)，随后给予[依托泊苷](https://www.uptodate.cn/contents/zh-Hans/92839?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(600-2400mg/m2)加[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(4.8g/m2-7.2g/m2)，分4日给予。这种方案通常用于治疗淋巴瘤患者。

全球不同医疗中心已使用了这些清髓性方案的许多变化形式。这些变化形式是通过增加照射剂量或某一特定药物的剂量至最大耐受量而制定出的。为避免对某特定器官的协同损伤，采用无重叠毒性的药物([表 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F54359&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))。(参见上文[‘定义’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H2))

清髓性方案的毒性 — 所有清髓性预处理方案都有可危及生命的副作用。除骨髓毒性外，常见毒性还包括：

●黏膜炎(参见 [“造血干细胞移植的早期并发症”，关于‘口腔黏膜炎’一节](https://www.uptodate.cn/contents/zh-Hans/early-complications-of-hematopoietic-cell-transplantation?sectionName=%E5%8F%A3%E8%85%94%E9%BB%8F%E8%86%9C%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H598162&source=see_link#H598162)和 [“全身性抗癌治疗的口腔毒性”](https://www.uptodate.cn/contents/zh-Hans/oral-toxicity-associated-with-systemic-anticancer-therapy?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●恶心和呕吐(参见 [“成人化疗所致恶心呕吐的预防和治疗”](https://www.uptodate.cn/contents/zh-Hans/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●脱发(参见 [“全身性癌症治疗所致脱发”](https://www.uptodate.cn/contents/zh-Hans/alopecia-related-to-systemic-cancer-therapy?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●腹泻(参见 [“化疗药物的肠毒性”](https://www.uptodate.cn/contents/zh-Hans/chemotherapy-associated-diarrhea-constipation-and-intestinal-perforation-pathogenesis-risk-factors-and-clinical-presentation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

●皮疹

●周围神经病(参见 [“常规非铂类癌症化疗药物的神经系统并发症概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-neurologic-complications-of-conventional-non-platinum-cancer-chemotherapy?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和 [“含铂化疗方案的神经系统并发症概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-neurologic-complications-of-platinum-based-chemotherapy?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

**在使用清髓性方案时，不孕/不育几乎是普遍存在的，这对年轻患者可是摧毁性的。如果男性患者具有充分的精子数量和功能，则对于男性患者，不育可以通过精子冷冻保存来解决。女性患者也可尝试胚胎或卵母细胞冷冻保存，其成功率一般较低** 。(参见 [“性腺毒性治疗或手术前保留生育力和生殖激素的概述”](https://www.uptodate.cn/contents/zh-Hans/fertility-and-reproductive-hormone-preservation-overview-of-care-prior-to-gonadotoxic-therapy-or-surgery?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

肺毒性和肝脏毒性也相对常见。例如，[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)是许多预处理方案中的一个组成部分，它可导致间质性肺疾病和肝窦阻塞综合征(sinusoidal obstructive syndrome, SOS)[[6,7](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/6,7)]。因此，在开始预处理方案前必须筛查患者有无共存疾病，以避免不必要的风险。监测白消安药动学是一种常见的做法，也可降低这些并发症的风险。(参见 [“白消安诱发的肺损伤”](https://www.uptodate.cn/contents/zh-Hans/busulfan-induced-pulmonary-injury?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和 [“确定适合异基因造血干细胞移植的患者”](https://www.uptodate.cn/contents/zh-Hans/determining-eligibility-for-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和 [“成人肝窦阻塞综合征(肝小静脉闭塞病)”](https://www.uptodate.cn/contents/zh-Hans/hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

含放疗的方案 — 根据在犬和其他动物模型中的早期研究，自开始HCT治疗以来，TBI就是预处理方案的主要部分。初始预处理方案包括使用相对的钴60源作为单剂给予的TBI[[8](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/8)]。目前以TBI为基础的方案通常分割照射，将总剂量分割为数日给予，通常为4日，这有助于减低毒性和增加耐受性([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F90901&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))[[9](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/9)]。并且包括进行部分肺屏蔽，以减少不可逆性肺损伤的可能性。

TBI的最大耐受剂量大约为15Gy。更高的剂量会产生过度的非血液学毒性，主要为肺毒性，也可对其他器官(包括心脏)产生毒性。2项随机试验评估了在达到首次缓解的急性髓系白血病(acute myeloid leukemia, AML)患者和处于慢性期的慢性髓系白血病(chronic myeloid leukemia, CML)患者进行异基因HCT前采用不同剂量TBI(12Gy和16Gy)加[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)的疗效[[10,11](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/10,11)]。结果发现，TBI较高剂量组的复发率较低(例如，AML患者在3年时复发率为12% vs 35%)，但总体生存率(overall survival, OS)相近，主要归因于较高剂量组的移植相关死亡率增加(例如，在3年时的移植相关死亡率为32% vs 12%)[[10](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/10)]。此观察结果是开发放射性标记的单克隆抗体作为预处理方案一部分的主要依据之一。(参见下文[‘放射性标记的单克隆抗体’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H10))

在初始方案中，应用TBI联合[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(Cy)，这一Cy/TBI联合方案目前仍被广泛使用。在Cy/TBI联合方案中，环磷酰胺通常按校正理想体重给予每日60mg/kg，连用2日[[12-14](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/12-14)]。通过增加TBI剂量或加用其他药物来进一步强化上述方案的尝试，未能成功改善OS，主要是由于非复发性死亡率增加。TBI也已与其他化疗药物联合应用，例如：

●[依托泊苷](https://www.uptodate.cn/contents/zh-Hans/92839?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(VP16)给予60mg/kg的最大耐受剂量与分割TBI联用[[15](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/15)]，很多患者获得了非常好的结果[[16,17](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/16,17)]。此外，VP16已联合[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和TBI(TBI/CY/VP16)用于自体和异基因移植，以降低高风险或进展期血液系统恶性肿瘤患者的复发率[[18-20](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/18-20)]。

●大剂量[阿糖胞苷](https://www.uptodate.cn/contents/zh-Hans/92802?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(通常为一次3g，每12小时1次，持续6日)也已联合TBI，加或不加[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)，用于急性白血病患者[[21,22](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/21,22)]。这一方案的理论基础是通过阿糖胞苷的抗白血病活性来降低疾病复发的可能性。但使用阿糖胞苷(而不是环磷酰胺)的可能优势仍未证实[[23](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/23)]。

在多机构试验中，由于存在剂量率、屏蔽和中心特异性技术的差异，相对难以标准化分割TBI。不同机器的剂量率有所差异，当使用高剂量率的机器时，必须给予较低的总剂量以限制毒性。分割照射可降低急性和晚期并发症的发生率和严重程度。较低的总剂量可能降低毒性，但会增加移植失败和疾病复发的风险。相反，较高的剂量可减少移植物排斥反应和疾病复发，但会增加治疗相关并发症发病率和死亡率。

分割TBI的主要局限性包括：黏膜炎、肺毒性、不孕/不育，以及需要相对复杂的仪器装置来有效给予这一治疗。然而，角质形成细胞生长因子(帕立非明)已成功降低了含照射的方案后发生黏膜炎的风险。(参见 [“造血干细胞移植的早期并发症”，关于‘口腔黏膜炎’一节](https://www.uptodate.cn/contents/zh-Hans/early-complications-of-hematopoietic-cell-transplantation?sectionName=%E5%8F%A3%E8%85%94%E9%BB%8F%E8%86%9C%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H598162&source=see_link#H598162))

TBI作为HCT预处理方案的一部分使用后，长期并发症常见。一项研究纳入了186例成人患者，这些患者在采用TBI和HCT后存活至少1年，这些患者被随访的中位时间为4年(范围为1-11年)，最常见的并发症包括[[24](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/24)]：

●无症状性肺功能改变–19%[[25](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/25)]

●白内障–15%；其中57%有必要进行手术

●干燥综合征–13%

●甲状腺功能减退–6.5%；一半需要内科治疗

●甲状腺炎–3%

很多中心正在转变为不使用以放疗为基础的方案，而优选以化疗为基础的方案。

无放疗的化疗方案 — 目前已开发出许多采用额外化疗药物替换TBI的方案[[26](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/26)]。这些方案主要被开发用于自体移植，但也已广泛用于异基因移植。无TBI的方案的主要优势是减少毒性。此外，其成本较低、方案更易实施和计划，而且在移植后仍可对病变部位给予照射[[27](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/27)]。

药物联合的选择是基于特定药物的生物学活性、增加该药物剂量的能力，以及在给予最大耐受剂量的数种药物时没有重叠毒性。最广泛使用的不含照射的预处理方案是[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)联合[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(Bu/Cy)方案[[6,28-34](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/6,28-34)]。[卡莫司汀](https://www.uptodate.cn/contents/zh-Hans/94065?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)、[依托泊苷](https://www.uptodate.cn/contents/zh-Hans/92839?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)、[阿糖胞苷](https://www.uptodate.cn/contents/zh-Hans/92802?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(BEAM)方案或卡莫司汀、依托泊苷和环磷酰胺方案，是NHL或霍奇金淋巴瘤患者广泛使用的预处理方案[[35](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/35)]。大剂量美法仑常用作多发性骨髓瘤自体HCT前的清髓性预处理方案。不同移植中心使用的药物剂量和方案存在差异，因而难以比较此方案在不同研究中的结果[[11,36-40](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/11,36-40)]。(参见上文[‘清髓性方案实例’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89396143))

初始Bu/Cy方案使用大剂量的口服[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)，必须在使用致呕吐药物之前给予，具有可变的药物代谢动力学，并且具有较高的肝SOS和癫痫发作发生率[[41](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/41)]。现代Bu/Cy方案使用的是静脉剂型白消安，其药物代谢动力学差异性较小，且毒性更少(致吐性较低，肝毒性较低)[[42](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/42)]。给予调整剂量(根据药理学评估进行调整)的静脉用白消安联合[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)，可得到非常好的结局，且耐受性改善[[43](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/43)]。应该在给予白消安前开始进行预防性抗癫痫治疗。

使用含[卡莫司汀](https://www.uptodate.cn/contents/zh-Hans/94065?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)的方案的一个严重问题是，肺毒性的发生率相对较高，尤其是既往已接受胸部放疗的患者[[44,45](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/44,45)]。这一并发症通常对皮质类固醇治疗(大约1mg/kg[泼尼松](https://www.uptodate.cn/contents/zh-Hans/92103?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)剂量)有反应，尤其是在其早期时。对于侵袭性或复发性淋巴瘤患者，尽量减少肺毒性的方法是联合使用[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)、[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和[塞替派](https://www.uptodate.cn/contents/zh-Hans/92841?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)，然后再行自体外周血祖细胞移植[[46](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/46)]。在40例采用此方案的患者中，仅1例既往接受过肺部放疗的患者发生了间质性肺炎。(参见 [“亚硝基脲类诱导的肺损伤”](https://www.uptodate.cn/contents/zh-Hans/nitrosourea-induced-pulmonary-injury?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

优选的预处理方案也可能因基础疾病性质的不同而异。例如，在再生障碍性贫血患者中，在增加免疫抑制程度(以预防移植物排斥反应)的同时避免过度的骨髓毒性是可取的。采用[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)联合ATG成功实现了此目标[[47](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/47)]。(参见上文[‘方案的选择’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89394187)和 [“造血细胞移植治疗成人再生障碍性贫血”](https://www.uptodate.cn/contents/zh-Hans/hematopoietic-cell-transplantation-for-aplastic-anemia-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

放疗和化疗的比较 — 对于已开发出的大量不同清髓性预处理方案，很难对其相对疗效进行比较，因为目前随机临床试验很少对其进行直接比较。此外，患者选择很可能对所获得的结果具有很大影响，这使得很难评估来自文献报道的大量Ⅱ期试验的任何特定预处理方案的影响。一项回顾性队列研究报道了一个具有指导性的实例，该研究在进行自体外周血干细胞移植的NHL患者中比较了含放疗的预处理方案(TBI/[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)/[依托泊苷](https://www.uptodate.cn/contents/zh-Hans/92839?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))与只有化疗的方案(BEAM)[[48](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/48)]。结果显示，含TBI方案的无复发生存(relapse-free survival, RFS)和OS与BEAM方案相近。进一步分析表明，2000年前进行的移植(而不是预处理方案)是长期结局的一个更重要的预测因素。

尽管存在这些困难，仍有一些回顾性和随机试验，包括一项meta分析，比较了Bu/Cy方案和Cy/TBI方案[[6,29,49,50](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/6,29,49,50)]：

●国际骨髓移植登记处回顾性地比较了下述两组处于首次缓解的AML患者在异基因HCT后的结局：381例接受Bu/Cy的具有HLA相合同胞的移植，以及200例采用Cy/TBI的移植[[50](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/50)]。结果显示：Bu/Cy组的肝SOS[以前称为肝小静脉闭塞病(veno-occlusive disease, VOD)]的发生率比Cy/TBI组高(13% vs 6%)，并且Bu/Cy组的复发风险也更高(RR 1.7，95%CI 1.05-2.81)。然而，两组间的治疗相关死亡率、急性或慢性GVHD风险、无白血病生存和OS无差异。

●对5项比较Bu/Cy方案和Cy/TBI方案的前瞻性随机研究进行的一项meta分析得出了类似的结论[[49](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/49)]，其结论为：Bu/Cy组的肝SOS风险增加(OR 2.5，95%CI 1.2-5.2)，但急性或慢性GVHD、间质性肺炎、无病生存和OS的差异无统计学意义。

这些研究并未根据药动学调整[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)剂量，这可能影响方案相关并发症(如肝SOS)。鉴于这些结果，许多研究组对骨髓疾病患者使用Bu/Cy预处理方案，而不是以TBI为基础的方案。(参见 [“成人肝窦阻塞综合征(肝小静脉闭塞病)”，关于‘可纠正的危险因素’一节](https://www.uptodate.cn/contents/zh-Hans/hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-adults?sectionName=%E5%8F%AF%E7%BA%A0%E6%AD%A3%E7%9A%84%E5%8D%B1%E9%99%A9%E5%9B%A0%E7%B4%A0&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H620894823&source=see_link#H620894823))

非清髓性和减低强度预处理方案

一般原则 — 白血病患者接受异基因HCT治疗，一个重要的促进因素是供者免疫活性细胞介导的GVT效应[[51](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/51)]。采用来自同卵双胎和不全同供者的移植物得出的不同结局，阐释了GVT效应的重要性。接受同卵双胎供体移植的患者不会发生GVHD，也没有GVT效应，因此基础恶性疾病的复发风险高于接受HLA匹配但不全同同胞供者移植的相似患者(既发生GVHD，也有GVT效应)。(参见 [“造血干细胞移植后移植物抗肿瘤效应的生物学”](https://www.uptodate.cn/contents/zh-Hans/biology-of-the-graft-versus-tumor-effect-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

GVT效应需要供者型免疫活性细胞植活，而这一植活并不一定需要大剂量的清髓性预处理方案。因此，目前已广泛探索了使用非清髓性或RIC方案获得供者特异性植活的可能性[[2,52-56](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/2,52-56)]。此方法更多地依赖于供者细胞免疫效应，较少依赖预处理方案的细胞毒作用来控制基础疾病[[51,57-59](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/51,57-59)]，该方法允许年龄较大的患者和具有高风险、既往进行了大量治疗的任何年龄患者进行移植，且相应的方案相关毒性和治疗相关死亡率(treatment-related mortality, TRM)较低[[60-68](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/60-68)]。(参见上文[‘定义’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H2))

在很多情况下，癌细胞不能被单纯的大剂量化疗完全根除(如，多发性骨髓瘤)，或者具有这些疾病的患者疾病太严重(因为年龄和/或共存疾病)而不能耐受清髓性化疗方案及其后移植[[61,69,70](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/61,69,70)]。许多观察到的长期肿瘤反应，是由同种异体移植物(例如，在异基因HCT后CML复发时进行的供者淋巴细胞输注)产生的免疫抗肿瘤效应(即，GVT效应)引起的[[51,71](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/51,71)]。

**重要的是，不是所有疾病都对GVT效应同样敏感。滤泡淋巴瘤、慢性淋巴细胞白血病、套细胞淋巴瘤和CML似乎对GVT效应特别敏感，而急性淋巴细胞白血病和霍奇金淋巴瘤则相对抵抗。对这些观察结果的生物学解释仍不清楚。例如，对834例已进行了异基因HCT的患者进行的一项分析显示，每患者年的总复发率为0.36。慢性淋巴细胞白血病、缓解期多发性骨髓瘤、低级别或套细胞淋巴瘤，以及高级别NHL患者的复发率最低(0-0.24)，而进展期髓系和淋巴系恶性肿瘤患者的复发率高于0.52** [[72](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/72)]。

仍需进一步研究确定此移植方法的相对作用，包括受者年龄和总体共存疾病状态、HCT时是否完全或部分缓解、基础疾病的临床侵袭性、供者HLA匹配程度、RIC及GVHD预防所用的药物和剂量等变量[[72-77](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/72-77)]。然而，这些方法即使在老年和具有显著共存疾病的患者中也可被相当好地耐受，从而使更多的患者可采用移植治疗。这一点很重要，因为很多已成功进行异基因HCT的疾病通常发生于40-70岁的患者。

非清髓性/RIC方案实例 — 关于非清髓性预处理方案和RIC方案定义的具体细节持续存在争议([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F90901&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))。一般来讲，RIC的毒性显著低于清髓性方案，但高于非清髓性方案。

常用的非清髓性方案包括[[5](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/5)]：

●**Flu/TBI**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)90mg/m2的总剂量，分3日给予，联合在输注移植物当日进行低剂量TBI(2Gy)。

●**TLI/ATG**–该方案为：全淋巴照射(total lymphoid irradiation, TLI，8-12cGy)分11日给予，联合ATG(1.25mg/kg)分5日给予。采用这一方法时，TLI和ATG似乎会改变宿主免疫状态，以利于抑制GVHD但保留移植物抗肿瘤效应的调节性自然杀伤T细胞[[78](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/78)]。对这一方法的初始研究结果显示出了前景性，其结果为急性GVHD风险明显降低，同时保留了GVT效应，且移植相关死亡率非常低[[79,80](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/79,80)]。

少数几项随机试验中的一项发现，与Flu/TBI方案相比，TLI/ATG方案的非复发性死亡风险较低，复发风险较高，两种方案的OS和无事件生存率相近[[81](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/81)]。

常用的RIC方案包括[[5](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/5)]：

●**Flu/Mel**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(总剂量125-150mg/m2)分5日给药，联合[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(140mg/m2)分2日给药。

●**Flu/Bu2**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(总剂量150-160mg/m2)分4-5日给药，联合口服[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(8-10mg/kg)分2-3日给药。

●**Flu/Cy**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(总剂量150-180mg/m2)分5-6日给药，联合[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(120-140mg/kg)分2日给药。

●**Flu/Bu/TT**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(总剂量150mg/m2)分3日给药，加[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(8mg/kg)分3日给药，加[塞替派](https://www.uptodate.cn/contents/zh-Hans/92841?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(5-10mg/m2)分1或2日给药。

●**Flu/Treo**–该方案为：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(150mg/m2)总剂量分5日给药，加曲奥舒凡[10g/(m2·d)输注2小时，治疗3日][[82](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/82)]。曲奥舒凡已获批在加拿大和欧洲使用，但在美国未获批准。

所有这些方案显示出了前景，被不同的中心应用。所有的方案都具有优点，且似乎可被较年长个体和具有显著共存疾病的患者(包括进行了既往自体移植的患者)相当好地耐受。

清髓性方案 vs RIC方案 — 由于很少有随机临床试验或其他良好对照研究，因此很难直接比较MAC与NMA/RIC或各种预处理方案的有效性和毒性。患者选择对结局有重要影响，各研究在患者人群、基础疾病、缓解状态和移植物来源方面有所不同。一般来说，与NMA/RIC方案相比，MAC方案与RFS更佳相关，但增加TRM；这些作用相互抵消，因此其OS与这两种方案相当。

提供有用信息研究的包括：

●一项纳入272例AML或骨髓增生异常综合征(myelodysplastic syndromes, MDS)患者的多中心3期试验报道，MAC后的复发少于RIC后，但生存情况无差异[[83](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/83)]。与RIC相比，MAC与更好的RFS相关(68% vs 47%)，但TRM更高(16% vs 4%)；因此，在18个月时OS无差异。该试验的后续分析显示，MAC的益处与移植前有可测量残留病(measurable residual disease, MRD)的患者结局改善有关[[84](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/84)]。该试验的更多细节见其他专题。(参见 [“年轻成人急性髓系白血病的缓解后治疗”，关于‘NMA/RIC方案 vs MAC方案’一节](https://www.uptodate.cn/contents/zh-Hans/post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults?sectionName=NMA%2FRIC%E6%96%B9%E6%A1%88+vs+MAC%E6%96%B9%E6%A1%88&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&anchor=H1914200632&source=see_link#H1914200632))

●一项前瞻性研究根据年龄调整AML成人患者的治疗，发现清髓性方案和RIC方案间的总生存率无差异[[85](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/85)]。

●AML或MDS的回顾性研究表明，RIC方案的复发率增加，治疗相关死亡率较低[[86-94](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/86-94)]。因此，尽管接受RIC方案的患者通常年龄较大且健康状况较差，但两种方法获得了相近的总生存率。

不同RIC方案的比较 — 不同减低强度方案的比较是基于非对照回顾性研究，因为没有随机化或良好对照的前瞻性试验[[95](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/95)]。

最低强度(抗体)预处理方案 — 部分患者，如具有严重器官毒性和/或DNA/端粒修复缺陷的患者，可能不能耐受清髓性方案，甚至不能耐受非清髓性方案，他们可能适合最低强度预处理方案(minimal intensity conditioning)。(参见 [“Hematopoietic cell transplantation for severe combined immunodeficiencies”](https://www.uptodate.cn/contents/hematopoietic-cell-transplantation-for-severe-combined-immunodeficiencies?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

一项针对16例因原发性联合免疫缺陷而进行异基因HCT的高风险患者的Ⅰ/Ⅱ期研究，检验了上述观念。此预处理方案包括使用2种鼠抗CD45抗体、1种抗CD52抗体(阿仑单抗)、[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)和低剂量[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)。结果如下[[96](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/96)]：

●有临床意义的急性和慢性GVHD的发生率分别为36%和31%，未见4级毒性。

●16例患者中15例植活，其中11例的淋系和髓系均达到完全性的或高水平性的混合嵌合状态。

●HCT后中位随访40个月时，16例患者中13例患者(81%)存活且其基础疾病治愈。

放射性标记的单克隆抗体 — 单克隆抗体与发射高能量的放射性同位素共轭，已用于增加靶向骨髓肿瘤细胞的放射剂量，并减少对肝、肺、肾等其他器官的放射剂量。这种方法尚未广泛应用于预处理方案。

但仍担忧，骨髓腔大剂量放射性可能损伤或杀灭骨髓基质细胞。此外，部分放射性同位素的此类大剂量给予需要复杂的专业技术、设备，以及对患者的屏蔽以避免对医护人员造成风险。

抗CD20放射免疫偶联物 — 抗CD20放射免疫偶联物已用于治疗B细胞NHL患者。例如，[替伊莫单抗](https://www.uptodate.cn/contents/zh-Hans/92832?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)是一种与钇-90共轭的鼠抗CD20单克隆抗体。

将抗CD20放射免疫偶联物加入标准预处理方案中，用于自体移植治疗B细胞NHL患者，其初步结果鼓舞人心且毒性可耐受[[97-100](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/97-100)]。一项随机试验报道，BEAM方案加抗CD20放射免疫偶联物与单用BEAM方案有相似的无进展生存率和总生存率[[101](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/101)]。

抗CD45抗体 — CD45在造血细胞上高度表达，抗CD45的单克隆抗体可将放射性同位素靶向作用于骨髓腔[[102,103](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/102,103)]。一项报道显示，与单纯使用Bu/Cy方案的注册数据相比，Bu/Cy方案加抗CD45单克隆抗体的结局更好[[104](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/104)]。很难给予I-131，这限制了其使用。

抗CD66抗体 — CD66高度表达于从早幼粒细胞至成熟粒细胞的正常髓系细胞上。一项报道中，30例因恶性疾病(16例)或非恶性疾病(14例)进行异基因HCT的儿科和青少年患者，接受了钇-90共轭CD66单克隆抗体联合RIC或清髓性预处理方案[[105](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/105)]。结果显示，抗体联合RIC方案使非恶性血液系统疾病患者获得一致的清髓和稳定的完全供体嵌合状态。

嵌合体 — 嵌合体是指供者和宿主细胞在骨髓中共存。嵌合体更常见于非清髓性预处理方案或RIC后，以及脐血移植后。对于许多遗传性疾病，混合的供体-宿主嵌合状态足以缓解疾病相关表现(如，重型β地中海贫血)。(参见 [“地中海贫血的造血干细胞移植后管理”](https://www.uptodate.cn/contents/zh-Hans/thalassemia-management-after-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

鉴于预处理方案的减低强度，以及诱导出部分供者嵌合状态，可应用供者白细胞输注[[106](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/106)]或其他免疫治疗性干预措施来平衡以下相互竞争的问题间的相互作用(参见 [“免疫治疗在预防和治疗异基因造血干细胞移植后复发中的应用”](https://www.uptodate.cn/contents/zh-Hans/immunotherapy-for-the-prevention-and-treatment-of-relapse-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))[[79,107-115](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/79,107-115)]：

●最大化GVT效应

●最小化急性和慢性GVHD

●最小化移植物排斥反应

●通过快速免疫重建，最小化机会性感染[如，巨细胞病毒(cytomegalovirus, CMV)感染][[116](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/116)]

这一方法极大地依赖于对供者和受者间嵌合体状态的连续评估，采用的技术有荧光原位杂交(fluorescence in situ hybridization, FISH)或可变数目串联重复序列(variable number of tandem repeats, VNTR)分析[[117-121](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/117-121)]。在性别不匹配的移植中，采用FISH对分裂间期细胞核中的X和Y染色体进行检查，是识别嵌合体的高度准确技术。

COVID-19大流行期间的特殊考虑COVID-19大流行增加了癌症诊疗的难度。重要问题包括权衡延迟诊疗的风险与COVID-19的危害，提供医疗服务时如何尽量减少因保持社交距离而产生的不利影响，以及公平合理地分配有限的医疗资源。COVID-19大流行期间的上述问题和癌症诊疗推荐详见其他专题。(参见 [“COVID-19：癌症患者的考虑事项”](https://www.uptodate.cn/contents/zh-Hans/covid-19-considerations-in-patients-with-cancer?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

患者教育UpToDate提供两种类型的患者教育资料：“基础篇”和“高级篇”。基础篇通俗易懂，相当于5-6年级阅读水平(美国)，可以解答关于某种疾病患者可能想了解的4-5个关键问题；基础篇更适合想了解疾病概况且喜欢阅读简短易读资料的患者。高级篇篇幅较长，内容更深入详尽；相当于10-12年级阅读水平(美国)，适合想深入了解并且能接受一些医学术语的患者。

以下是与此专题相关的患者教育资料。我们建议您以打印或电子邮件的方式给予患者。(您也可以通过检索“患者教育”和关键词找到更多相关专题内容。)

●高级篇(参见 [“Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)”](https://www.uptodate.cn/contents/hematopoietic-cell-transplantation-bone-marrow-transplantation-beyond-the-basics?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link))

总结

●**预处理方案**是造血干细胞移植(HCT)操作中一个至关重要的部分。预处理方案的目的有两个：

•提供充分的免疫抑制以防止移植物排斥反应

•治疗需要进行移植的基础疾病

●**分类**–HCT预处理方案的药物(如化疗、免疫治疗、放疗)、清髓强度和程度有所不同。普遍接受的定义如下([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=HEME%2F90901&topicKey=HEME%2F3557&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=see_link))：

•**清髓性预处理方案**–由预计可破坏骨髓造血细胞的单药或数种药物联合组成，可引起严重的全血细胞减少。其引起的全血细胞减少持续很长时间，通常不可逆转，除非输注造血干细胞恢复造血功能。例如全身照射(TBI)≥5Gy或口服[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)>8mg/kg。(参见上文[‘清髓性预处理方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H5))

•**非清髓性预处理方案**–指本身导致轻微血细胞减少(但引起显著的淋巴细胞减少)且无需干细胞支持的方案。例如[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)加[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)，联合或不联合[抗胸腺细胞球蛋白](https://www.uptodate.cn/contents/zh-Hans/133562?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)(ATG)，或TBI≤2Gy联合或不联合嘌呤类似物。然而，此情况下移植通常可产生完全的供体植活，因为植活的供者T细胞最终将清除宿主造血细胞，从而允许建立供者造血功能。(参见上文[‘非清髓性和减低强度预处理方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89394696))

•**减低强度预处理方案(RIC)**–RIC是既不符合清髓性方案定义也不符合非清髓性方案定义的中间类别方案。此类方案可引起血细胞减少，且可能持续较长时间并导致显著的并发症和死亡，需要干细胞支持。≤8mg/kg的口服[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)或≤140mg/m2的[美法仑](https://www.uptodate.cn/contents/zh-Hans/92848?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=3557&source=see_link)一般被视为RIC方案。

●**MAC方案选择**–方案选择通常取决于机构和医生的偏好和经验。几乎没有随机试验针对特定疾病直接比较不同MAC预处理方案的有效性。(参见上文[‘方案的选择’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89394187))

●**清髓性预处理方案 vs RIC/非清髓性预处理方案**–清髓性预处理方案通常复发率较低，但治疗相关死亡率和并发症发生率较高；因此，大多数研究提示清髓性预处理方案与RIC/非清髓性预处理方案的OS相当。(参见上文[‘清髓性方案 vs RIC方案’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H3000363872))

●**不良反应**–除了骨髓毒性外，所有预处理方案都还有短期和长期不良反应。其他常见的毒性包括：黏膜炎、恶心和呕吐、脱发、腹泻、皮疹、外周神经病、不孕/不育、间质性肺疾病和肝窦阻塞综合征(SOS)。TBI后的长期并发症还包括无症状的肺功能改变、白内障、干燥综合征和甲状腺功能障碍。(参见上文[‘清髓性方案的毒性’](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link#H89396547))

使用UpToDate临床顾问须遵循[使用条款](https://www.uptodate.cn/legal/china/license).

参考文献

1.  [Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/1)
2.  [Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111:18.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/2)
3.  [Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/3)
4.  [Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15:1628.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/4)
5.  Gratwohl A, Carreras E. Principles of Conditioning. In: ESH-EBMT Handbook on Haematopoietic Stem Cell Transplantation 2012, 6th edition, Apperley J, Carreras E, Gluckman E, Masszi T (Eds), European School of Haematology, Paris 2012. p.126.
6.  [Ringdén O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93:2196.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/6)
7.  [Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16:166.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/7)
8.  [Buckner CD, Epstein RB, Rudolph RH, et al. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970; 35:741.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/8)
9.  [Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9:1607.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/9)
10.  [Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/10)
11.  [Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/11)
12.  [Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292:832.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/12)
13.  [Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982; 8:817.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/13)
14.  [Santos GW, Sensenbrenner LL, Burke PJ, et al. Allogeneic marrow grafts in man using cyclophosphamide. Transplant Proc 1974; 6:345.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/14)
15.  [Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69:1015.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/15)
16.  [Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82:2920.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/16)
17.  [Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84:1672.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/17)
18.  [Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3:324.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/18)
19.  [Horning SJ, Negrin RS, Chao JC, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2552.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/19)
20.  [Weaver CH, Petersen FB, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12:2559.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/20)
21.  [Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6:576.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/21)
22.  [Jillella AP, Doria R, Khan K, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant 1999; 23:1095.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/22)
23.  [Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990; 6:9.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/23)
24.  [Thomas O, Mahé M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49:125.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/24)
25.  [Gopal R, Ha CS, Tucker SL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92:1949.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/25)
26.  [Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80:1648.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/26)
27.  [Shah AB, Hartsell WF, Ghalie R, Kaizer H. Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy. Int J Radiat Oncol Biol Phys 1995; 32:1433.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/27)
28.  [Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70:1382.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/28)
29.  [Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/29)
30.  [O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/30)
31.  [Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/31)
32.  [Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10:237.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/32)
33.  [Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998; 850:270.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/33)
34.  [Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31:701.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/34)
35.  [Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/35)
36.  [Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993; 81:319.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/36)
37.  [Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/37)
38.  [Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8:648.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/38)
39.  [Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9:1871.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/39)
40.  [Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/40)
41.  [Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/41)
42.  [Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114:944.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/42)
43.  [Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102:31.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/43)
44.  [Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6:1368.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/44)
45.  [Valteau D, Hartmann O, Benhamou E, et al. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/45)
46.  [Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3:261.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/46)
47.  [Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89:3890.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/47)
48.  [Liu HW, Seftel MD, Rubinger M, et al. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2010; 78:513.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/48)
49.  [Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22:439.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/49)
50.  [Litzow MR, Pérez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119:1115.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/50)
51.  [Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8:2.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/51)
52.  [Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11:87.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/52)
53.  [Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol 1999; 6:383.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/53)
54.  [Little MT, Storb R. The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000; 105:1679.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/54)
55.  [Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111:6.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/55)
56.  [Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004; 103:1560.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/56)
57.  [Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343:750.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/57)
58.  [Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101:469.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/58)
59.  [Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31:1530.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/59)
60.  [Saito T, Kanda Y, Kami M, et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8:1014.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/60)
61.  [Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/61)
62.  [Belkacémi Y, Labopin M, Hennequin C, et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 2007; 67:544.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/62)
63.  [Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104:1550.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/63)
64.  [Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/64)
65.  [Corradini P, Zallio F, Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 2005; 23:6690.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/65)
66.  [Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/66)
67.  [Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114:1429.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/67)
68.  [McClune BL, Weisdorf DJ. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol 2010; 17:133.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/68)
69.  [Hermann S, Klein SA, Jacobi V, et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001; 113:446.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/69)
70.  [Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103:435.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/70)
71.  [MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110:12.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/71)
72.  [Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110:2744.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/72)
73.  [Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/73)
74.  [Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130:575.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/74)
75.  [Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25:690.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/75)
76.  [Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008; 42:297.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/76)
77.  [Ciurea SO, Saliba R, Rondon G, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010; 45:429.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/77)
78.  [Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009; 113:4458.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/78)
79.  [Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353:1321.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/79)
80.  [Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114:1099.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/80)
81.  [Baron F, Zachée P, Maertens J, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol 2015; 8:4.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/81)
82.  [Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 2020; 7:e28.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/82)
83.  [Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 2017; 35:1154.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/83)
84.  [Hourigan CS, Dillon LW, Gui G, et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol 2020; 38:1273.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/84)
85.  [Lioure B, Béné MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012; 119:2943.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/85)
86.  [Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/86)
87.  [Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/87)
88.  [Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20:322.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/88)
89.  [Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/89)
90.  [Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12:1047.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/90)
91.  [Flynn CM, Hirsch B, Defor T, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82:867.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/91)
92.  [Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/92)
93.  [Luger SM, Ringdén O, Zhang MJ, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47:203.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/93)
94.  [Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28:2859.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/94)
95.  [Eapen M, Brazauskas R, Hemmer M, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv 2018; 2:2095.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/95)
96.  [Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009; 374:912.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/96)
97.  [Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25:1396.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/97)
98.  [Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:90.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/98)
99.  [Gopal AK, Guthrie KA, Rajendran J, et al. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118:1132.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/99)
100.  [Devizzi L, Guidetti A, Seregni E, et al. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. J Clin Oncol 2013; 31:2974.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/100)
101.  [Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013; 31:1662.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/101)
102.  [Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/102)
103.  [Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/103)
104.  [Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107:2184.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/104)
105.  [Schulz AS, Glatting G, Hoenig M, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/105)
106.  [Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103:790.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/106)
107.  [Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104:961.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/107)
108.  [Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99:75.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/108)
109.  [Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99:1071.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/109)
110.  [Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/110)
111.  [Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/111)
112.  [Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102:470.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/112)
113.  [Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103:1548.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/113)
114.  [Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2006; 132:36.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/114)
115.  [Sala-Torra O, Martin PJ, Storer B, et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 2008; 41:887.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/115)
116.  [Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135:524.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/116)
117.  [Wäsch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000; 109:743.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/117)
118.  [de Weger RA, Tilanus MG, Scheidel KC, et al. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110:647.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/118)
119.  [Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/119)
120.  [Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35:107.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/120)
121.  [Michallet AS, Fürst S, Le QH, et al. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. Br J Haematol 2005; 128:676.](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation/abstract/121)